INR 12.21
(-0.41%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 31.71 Million INR | -89.99% |
2022 | 113.59 Million INR | 30.95% |
2021 | 86.43 Million INR | 38.16% |
2020 | 44.42 Million INR | -13.3% |
2019 | 29.99 Million INR | 80.43% |
2018 | 40.4 Million INR | -9.88% |
2017 | 44.52 Million INR | 1.56% |
2016 | 44.09 Million INR | 17.5% |
2015 | 37.31 Million INR | -6.11% |
2014 | 39.74 Million INR | 19.21% |
2013 | 33.33 Million INR | 79.39% |
2012 | 18.58 Million INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 23.44 Million INR | 147.12% |
2023 Q2 | 29.54 Million INR | 10.69% |
2023 Q3 | 29.52 Million INR | -0.06% |
2023 Q4 | -67.8 Million INR | -329.64% |
2023 FY | - INR | -89.99% |
2023 Q1 | 26.69 Million INR | 103.75% |
2022 Q1 | 26.32 Million INR | 80.07% |
2022 Q2 | 33.3 Million INR | 26.51% |
2022 Q3 | 40.84 Million INR | 22.64% |
2022 Q4 | 13.1 Million INR | -67.93% |
2022 FY | - INR | 30.95% |
2021 FY | - INR | 38.16% |
2021 Q4 | 14.62 Million INR | -47.67% |
2021 Q3 | 27.94 Million INR | 8.26% |
2021 Q2 | 25.81 Million INR | 40.47% |
2021 Q1 | 18.37 Million INR | 75.12% |
2020 FY | - INR | -13.3% |
2020 Q4 | 10.49 Million INR | -65.13% |
2020 Q3 | 30.08 Million INR | 81.26% |
2020 Q2 | 16.59 Million INR | 201.25% |
2020 Q1 | 5.51 Million INR | -86.96% |
2019 Q1 | 6.43 Million INR | 12.41% |
2019 FY | - INR | 80.43% |
2019 Q4 | 42.25 Million INR | 335.92% |
2019 Q3 | 9.69 Million INR | -34.92% |
2019 Q2 | 14.89 Million INR | 131.47% |
2018 Q3 | 5.68 Million INR | 22.92% |
2018 Q2 | 4.62 Million INR | 0.0% |
2018 Q1 | 4.62 Million INR | -51.22% |
2018 FY | - INR | -9.88% |
2018 Q4 | 5.72 Million INR | 0.75% |
2017 Q3 | 9.52 Million INR | 111.19% |
2017 Q1 | 4.5 Million INR | 0.0% |
2017 Q2 | 4.5 Million INR | 0.0% |
2017 Q4 | 9.47 Million INR | -0.47% |
2017 FY | - INR | 1.56% |
2016 FY | - INR | 17.5% |
2015 FY | - INR | -6.11% |
2014 FY | - INR | 19.21% |
2013 FY | - INR | 79.39% |
2012 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 9.61 Billion INR | 99.67% |
Hester Biosciences Limited | 539.47 Million INR | 94.122% |
Aarti Drugs Limited | 3.24 Billion INR | 99.024% |
Aarti Pharmalabs Limited | 3.9 Billion INR | 99.189% |
Albert David Limited | 1.04 Billion INR | 96.967% |
Alembic Limited | 1.11 Billion INR | 97.159% |
Alkem Laboratories Limited | 24.19 Billion INR | 99.869% |
Bafna Pharmaceuticals Limited | 114.58 Million INR | 72.325% |
Bajaj HealthCare Limited | 406.23 Million INR | 92.194% |
Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -144.006% |
Brooks Laboratories Limited | 41.72 Million INR | 24.005% |
Eris Lifesciences Limited | 6.98 Billion INR | 99.546% |
FDC Limited | 3.38 Billion INR | 99.063% |
Glenmark Life Sciences Limited | 6.86 Billion INR | 99.538% |
Gufic Biosciences Limited | 1.48 Billion INR | 97.858% |
Hikal Limited | 2.69 Billion INR | 98.822% |
Ind-Swift Limited | 1.06 Billion INR | 97.023% |
Innova Captab Limited | 1.66 Billion INR | 98.099% |
IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 98.783% |
Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 90.196% |
Jubilant Pharmova Limited | 8 Billion INR | 99.604% |
Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 97.639% |
Lupin Limited | 36.96 Billion INR | 99.914% |
Mangalam Drugs & Organics Limited | 174.94 Million INR | 81.874% |
Medico Remedies Limited | 129.09 Million INR | 75.436% |
Morepen Laboratories Limited | 1.72 Billion INR | 98.163% |
Nectar Lifesciences Limited | 1.53 Billion INR | 97.935% |
Orchid Pharma Limited | 1.41 Billion INR | 97.766% |
Procter & Gamble Health Limited | 3.07 Billion INR | 98.969% |
RPG Life Sciences Limited | 1.28 Billion INR | 97.525% |
Kilitch Drugs (India) Limited | 287.42 Million INR | 88.967% |
Sigachi Industries Limited | 883.39 Million INR | 96.41% |
Solara Active Pharma Sciences Limited | -2.82 Billion INR | 101.124% |
Suven Pharmaceuticals Limited | 4.67 Billion INR | 99.322% |
Themis Medicare Limited | 562.6 Million INR | 94.364% |
Unichem Laboratories Limited | 742.35 Million INR | 95.728% |
Wanbury Limited | 985.49 Million INR | 96.782% |
Windlas Biotech Limited | 781.72 Million INR | 95.943% |
ZIM Laboratories Limited | 462.09 Million INR | 93.138% |
Ind-Swift Laboratories Limited | 6.86 Billion INR | 99.538% |
Ipca Laboratories Limited | 13.29 Billion INR | 99.762% |
Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.977% |
Venus Remedies Limited | 711.8 Million INR | 95.545% |
Sakar Healthcare Limited | 393.26 Million INR | 91.937% |
Aurobindo Pharma Limited | 61.78 Billion INR | 99.949% |
Divi's Laboratories Limited | 25.43 Billion INR | 99.875% |
AstraZeneca Pharma India Limited | 2.35 Billion INR | 98.654% |
Mankind Pharma Limited | 28.09 Billion INR | 99.887% |
Sequent Scientific Limited | 549.8 Million INR | 94.232% |
Laurus Labs Limited | 8 Billion INR | 99.604% |
Neuland Laboratories Limited | 4.74 Billion INR | 99.332% |
J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 99.66% |
Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 99.72% |
Zydus Lifesciences Limited | 56.22 Billion INR | 99.944% |
Amrutanjan Health Care Limited | 681.59 Million INR | 95.348% |
Wockhardt Limited | 1.08 Billion INR | 97.064% |
Bal Pharma Limited | 345.59 Million INR | 90.824% |
Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.964% |
Bliss GVS Pharma Limited | 1.47 Billion INR | 97.856% |
Par Drugs and Chemicals Limited | 228.17 Million INR | 86.102% |
Caplin Point Laboratories Limited | 6.18 Billion INR | 99.487% |
Shilpa Medicare Limited | 2.58 Billion INR | 98.775% |
Valiant Laboratories Limited | 12.73 Million INR | -148.928% |
Ajanta Pharma Limited | 12.56 Billion INR | 99.748% |
Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | 29.789% |
Granules India Limited | 8.6 Billion INR | 99.631% |
Medicamen Biotech Limited | 245.66 Million INR | 87.092% |
Syncom Formulations (India) Limited | 430.27 Million INR | 92.63% |
Piramal Enterprises Limited | -3.86 Billion INR | 100.821% |
Torrent Pharmaceuticals Limited | 35 Billion INR | 99.909% |
NATCO Pharma Limited | 18.79 Billion INR | 99.831% |
Suven Life Sciences Limited | -992.78 Million INR | 103.194% |
Krebs Biochemicals & Industries Limited | -82.72 Million INR | 138.332% |
Strides Pharma Science Limited | 3.76 Billion INR | 99.158% |
Indoco Remedies Limited | 2.64 Billion INR | 98.802% |
Alpa Laboratories Limited | 229.96 Million INR | 86.21% |
Lasa Supergenerics Limited | -65.08 Million INR | 148.726% |
Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 100.85% |